echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA sub-issue: Silent, but can increase the risk of fractures by 34%! This type of thyroid dysfunction is worth paying attention to!

    JAMA sub-issue: Silent, but can increase the risk of fractures by 34%! This type of thyroid dysfunction is worth paying attention to!

    • Last Update: 2022-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Thyroid dysfunction is a recognized risk factor
    for bone-related outcomes, including fractures.
    Clinical hyperthyroidism accelerates bone resorption without compensatory bone formation, reduces bone mineral density, and increases fracture risk
    .
    Patients with overt thyroid dysfunction are usually symptomatic, easy to diagnose, and can be treated
    according to clinical guidelines.

    In the general adult population, the prevalence of subclinical hypothyroidism is estimated at 12%, while subclinical hyperthyroidism is less common, with an estimated prevalence of approximately 5%
    in US adults.
    In addition, subclinical thyroid dysfunction appears to persist in chronic conditions in approximately 60% of individuals and is more prevalent
    in older adults.
    However, the association between subclinical hyperthyroidism and fracture risk is currently unclear
    .
    Therefore, this study aimed to investigate the association
    between endogenous subclinical thyroid dysfunction and fracture risk.

    This cohort study included 10,946 participants from the Atherosclerosis Risk Study in the Community who were not taking thyroid medications and had no history
    of fractures.
    Subclinical hyperthyroidism is defined as thyroid-stimulating hormone levels below 0.
    56 mIU/L, subclinical hypothyroidism as thyrotropin levels greater than 5.
    1 mIU/L, normal thyroid function as 0.
    56 to 5.
    1 mIU/L, and normal free thyroxine levels of 0.
    85 to 1.
    4 ng/dL
    .

    Results showed that among 10,946 participants (54.
    3% were women; Mean [SD] age, 57 [5.
    7] years), 93.
    0% had euthyroidism, 2.
    6% had subclinical hyperthyroidism, and 4.
    4% had subclinical hypothyroidism
    .
    During the median follow-up of 21 years (IQR, 13.
    0 to 27.
    3 years), there were 3556 fracture inpatient or outpatient events (167.
    1 fractures per 10,000 person-years).

    The incidence of fractures per 10,000 people per 10,000 people with subclinical hypothyroidism was 180.
    8 (95% CI, 155.
    5 to 210.
    3) in patients with normal thyroid function, 165.
    8 (160.
    3 to 171.
    6) in patients with normal thyroid function, and 192.
    7 (157.
    8 to 235.
    4)
    in patients with subclinical hyperthyroidism.

    The fracture-adjusted risk ratio for patients with subclinical hyperthyroidism was 1.
    34 (95% CI, 1.
    09 to 1.
    65); There was no evidence of an association between subclinical hypothyroidism and fracture risk (HR, 0.
    90 [95% CI, 0.
    77-1.
    05]).

    In patients with normal free thyroxine levels, thyrotropin levels below the normal range were significantly associated with a higher risk of fracture-related hospitalization; Individuals with thyroid-stimulating hormone concentrations below 0.
    56 mIU/L are at greater risk
    of fracture.

    This community-based cohort study showed that subclinical hyperthyroidism is an independent risk factor
    associated with fracture.
    The increased risk of fracture in individuals with thyroid-stimulating hormone levels below 0.
    56 mIU/L highlights the potential role
    of more aggressive screening and surveillance of patients with subclinical hyperthyroidism to prevent osteomineral disease.

     

    Original source:

    Daya NR, Fretz A, Martin SS, et al.
    Association Between Subclinical Thyroid Dysfunction and Fracture Risk.
    JAMA Netw Open.
    2022; 5(11):e2240823.
    doi:10.
    1001/jamanetworkopen.
    2022.
    40823

     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.